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Tallahassee, FloridaABSTRACT Three HCM-causing tropomyosin (Tm) mutants (V95A, D175N, and E180G) were examined using the thin-
filament extraction and reconstitution technique. The effects of Ca2þ, ATP, phosphate, and ADP concentrations on cross-bridge
kinetics in myocardium reconstituted with each of these mutants were studied at 25C, and compared to wild-type (WT) Tm at
physiological ionic strength (200 mM). All three mutants showed significantly higher (2–3.5 fold) low Ca2þ tension (TLC) and
stiffness than WT at pCa 8.0. High Ca2þ tension (THC) was significantly higher for E180G than that for WT, whereas THC of
V95A and D175N was similar to WT; high Ca2þ stiffness (YHC) had the same trend. The Ca
2þ sensitivity of isometric force
was significantly greater for V95A and E180G than for WT, whereas that of D175N remained the same as for WT; for all mutants,
cooperativity was lower than for WT. Nine kinetic constants and the cross-bridge distribution were deduced using sinusoidal
analysis. The number of force-generating cross bridges was similar among the D175N, E180G, and WT Tm forms, but it was
significantly larger in the case of V95A than WT. We conclude that the increased number of actively cycling cross bridges at
pCa 8 is the major cause of Tm mutation-related HCM pathogenesis, which may result in diastolic dysfunction. Decreased
contractility (Tact) in V95A and D175N may further contribute to the severity of myocyte hypertrophy and related prognosis of
the disease.INTRODUCTIONInherited forms of hypertrophic cardiomyopathy (HCM) are
the most common genetic disorders of the heart caused by
sarcomeric protein mutations (1,2). HCM affects ~1 in
500 individuals; it is the leading cause of sudden death in
young adults and a major cause of mortality in elderly
people (3,4). The clinical and pathological manifestations
of HCM are highly variable, and include myocyte hyper-
trophy and disarray, interstitial fibrosis, and thickening of
the tunica media (smooth muscle layer) of coronary arteries.
Affected individuals can remain asymptomatic, or experi-
ence consequences as serious as severe heart failure or
sudden cardiac death (5,6).
Despite the interest these consequences have generated in
the study of HCM, the molecular pathogenesis under the
most common phenotypes of HCM, the maladaptive hyper-
trophy of the left ventricle, and the basis of phenotypic
diversity, remain unknown (7). Several hypotheses have
been proposed for possible molecular mechanisms leading
to HCM pathogenesis, such as decreased myocardial con-
tractility (8), disturbed myofibril formation (9,10), enhanced
actin-activated ATPase activity and force generation (11),
altered Ca2þ sensitivity (12), and impaired myocyte relaxa-
tion (13). Among these possibilities—which are not mutu-
ally exclusive—impaired myocyte relaxation has been
extensively studied because HCM is considered to be a
prototype for diastolic heart failure (14). Symptoms of im-
paired myocyte relaxation include decreased relaxationSubmitted October 5, 2010, and accepted for publication January 3, 2011.
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0006-3495/11/02/1014/10 $2.00velocity (13), reduced left-ventricular end-diastolic volume
(15), and enhanced left-ventricular end-diastolic pressure
(14). The cause of impaired relaxation is not clear, although
thickening of myocardium, structural changes related to
cellular disorganization, enhanced interstitial fibrosis, and
elevated Ca2þ sensitivity are all known to contribute to
severe alterations in diastolic properties of the myocardium
(12,16).
Although data from genotype-phenotype studies are
limited, it is generally recognized that specific mutations
do not always lead to a particular phenotype (17–19).
Similar clinical manifestations can be found in patients
with different mutations in sarcomeric proteins (20,21). It
has therefore been suggested that the treatment of HCM
patients can only be effective if it is different among
HCM patients according to the specific sarcomere gene
mutation that is involved (22). If this is the case, it is then
of critical significance that HCM pathogenesis be addressed
within the mutations of each individual gene.
So far, >400 mutations of sarcomeric proteins have been
identified to cause HCM (23). Among these proteins are the
cardiac thin filament proteins: actin (ACTC), troponin T
(TNNT2), troponin I (TNNI3), and a-tropomyosin (Tm)
(TPM1). In the case of a-Tm, 11 missense mutations have
been associated with HCM. A helical coiled-coil Tm mole-
cule has quasirepeating, loosely similar regions 1–7 (24),
and regional deletion/replacement studies have suggested
that each Tm region may contribute to a specific function
(25–28). The mutation V95A is located in region 3 and
mutations D175N and E180G are located in region 5.
Although their pathophysiological mechanisms are notdoi: 10.1016/j.bpj.2011.01.001
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thought to destabilize the coiled-coil structure of the Tm
dimer, and to increase local flexibility (29,30) because
they are at the g- and e-positions, respectively, of the heptad
repeat. These positions are typically occupied by ionic
amino-acid residues, which enable electrostatic attraction
between the two a-helices of the Tm dimer. In addition,
these mutations may affect the Tm-TnT interaction, because
Tm residues 175–190 (region 5) are known to interact with
TnT2 (26).
In Tm-associated HCM, it has been hypothesized that the
disease state is related to impaired relaxation caused by
increased Ca2þ sensitivity. For example, the D175N muta-
tion is known to increase Ca2þ sensitivity of both biopsy
tissue from patients (31) and the hearts of transgenic mice
that expressed 65% D175N protein (32,33). In another study
this mutation did not significantly affect Ca2þ sensitivity
(34) after adenovirus-mediated gene transfer, which may
be related to lower expression level (~60%) obtained with
this technique. E180G is known to increase Ca2þ sensitivity
in hearts of transgenic mice (35) as well as in cardiac cells
transfected using adenoviral vectors (34). E180G is also
known to decrease actin affinity both in the presence and
absence of troponin (Tn) (36). Both D175N and E180G
have been shown to be defective in promoting the myosin-
S1 activated switch of the thin filament from the closed to
open state, presumably because of the impaired TnT2 inter-
action (36). Moreover, V95A, as well as A63V and K70T,
are also known to cause an increase in Ca2þ sensitivity
in vitro (37,38).
However, all of the previous studies lack the direct
measurement of cross-bridge cycling kinetics, and concom-
itant force generation and stiffness increase within the
myocardium system under diastolic conditions. In this
report, the effect of three HCM-related Tm mutants
(V95A, D175N, and E180G) on force generation, stiffness,
and cross-bridge kinetics were studied using the thin fila-
ment removal/reconstitution technique combined with sinu-
soidal analysis (39–41). Our results demonstrate:
1. Impaired relaxation of myocardium, shown by the signif-
icantly elevated cross-bridge cycling and increased
isometric tension at pCa 8.0 with all three mutants.
2. Decreased myocardial contractility, as indicated by the
significant decrease in Ca2þ-activatable tension with
mutants V95A and D175N.MATERIAL AND METHODS
Experimental material and thin-filament
extraction and reconstitution technique
We used thin, slender bundles (length ~2 mm, diameter 90–110 mm) from
bovine cardiac muscle for thin-filament extraction and reconstitution and
mechanical measurements. These bundles were dissected from trabeculae
(see the Supporting Material) that were freely suspended in the rightventricle and stored in the skinning/storage solutions for at least seven
days. Bundles were attached to the experimental apparatus by nail polish,
and further skinned in 1% Triton X100 for 20 min in relaxing solution.
They were then stretched to the sarcomere length of ~2.1 mm, and thin-
filament extraction and reconstitution was performed. This technique
was originally developed in Ishiwata’s laboratory (40), refined in Kawai’s
laboratory (41), and was performed as described (25,39–41) with minor
modifications (see the Supporting Material).Proteins
G-actin was purified from rabbit fast-twitch skeletal muscles (43), and Tn
was purified from bovine hearts in Kawai’s Lab as described (44). Human
wild-type (WT) and mutant a-Tms were expressed as recombinant proteins
in Escherichia coli and purified at The Florida State University (Tallahas-
see, FL). Pure WT or mutant Tm was used in the reconstitution. These
Tms have two extra amino acids, Gly-Ser, which remain at the N-terminus
after removal of an affinity tag, and functionally substitute for acetylation
(45). These residues remain at the N-terminus after removal of an affinity
tag, and functionally substitute for acetylation (45). Previous studies
showed that this N-terminal difference had little effect on Tm stability
and function, either in vitro (46) or in fiber studies at physiological ionic
strength (28).pCa-tension and pCa-stiffness studies
pCa-tension and pCa-stiffness studies were performed as described in
Kawai et al. (28) except that the pCa range used in this study was from
8.0 to 4.66. The tension and stiffness under pCa 8 were called low Ca2þ
tension (TLC) and low Ca
2þ stiffness (YLC). The tension and stiffness under
pCa 4.66 were called high Ca2þ tension (THC) and high Ca
2þ stiffness
(YHC). Tension baseline was defined as that existing in the relaxing solution
(see Table S2 in the Supporting Material), which contains 6 mM EGTA, no
added Ca, and 40 mM BDM at 0C. There is no significant tension in this
condition. Subsequent tension measurements were performed as the incre-
ment from this baseline tension. The pCa-tension relationship of reconsti-
tuted fibers was studied with 12 different Ca2þ concentrations (pCa: 8.0,
7.5, 7.0, 6.4, 6.2, 6.0, 5.8, 5.6, 5.4, 5.2, 5.0, 4.66) with fixed MgATP
(5 mM) and Pi (8 mM) concentrations. The pCa-tension data were fitted






nH þ TLC; (1)
where pCa ¼ –log10[Ca2þ], Tact is the Ca2þ activatable tension (Tact ¼
THC – TLC), and Ca50 is the apparent Ca
2þ dissociation constant, which
represents the Ca2þ concentration at half-maximum tension. pCa50
(¼ –log10Ca50) represents Ca2þ sensitivity, and nH (Hill factor) represents
the cooperativity. pCa-tension curves were individually fitted to Eq. 1, and
the results were averaged. All tension values were normalized to unregu-
lated maximum tension (Ta; see section S1.2 in the Supporting Material)
of the actin-filament reconstituted myocardium without Tm or Tn, obtained
under our standard activating condition with the 5S8P solution (5 mM
MgATP, 8 mM Pi, pCa 4.66) at 25C. Ta averaged to 13.9 5 0.6 kPa
(n ¼ 51). Yact is defined as Yact ¼ YHC–YLC.Sinusoidal analysis
The elementary steps of the cross-bridge cycle based on six states (Scheme 1)
were characterized by sinusoidal analysis performed as described in Kawai
and Brandt (47) and Kawai et al. (48). Small amplitude (0.125% L0) sinu-
soidal length changes were applied to the reconstituted myocardium atBiophysical Journal 100(4) 1014–1023
SCHEME 1 Elementary steps of the cross-bridge cycle. The uppercase letters K indicate the association or equilibrium constants, and the lowercase letters
k indicate the rate constants of the elementary steps. Collectively these are called the kinetic constants, and they can be deduced experimentally. (A, actin;
M, myosin; D, MgADP; S, MgATP; and P, phosphate (Pi).) Rearranged from Kawai and Candau (80).
1016 Bai et al.18 different frequencies (f) in the range 0.13–100 Hz. The resulting tension
transients were analyzed and the complex modulus Y(f) was calculated. Y(f)
is the ratio of the stress change to the strain change expressed in the
frequency domain. Y(f) was then fitted to Eq. 2, which incorporates three
exponential processes (47)—Process A, Process B, and Process C—as
Yðf Þ ¼ H þ Afi
a þ fi
Bfi
b þ fi þ
Cfi
c þ fi; (2)
where i ¼ ﬃﬃﬃﬃﬃﬃ1p ; 2pa, 2pb, and 2pc are the apparent rate constants of
exponential processes A, B, and C, respectively; A, B, and C are their
respective magnitudes (sometimes called amplitudes); and H is a constant.
A, B, C, and H have the same units as Y(f) or isometric tension, and thus
are normalized to Ta. In cardiac muscle fibers, Process Awas not observed
(A ¼ 0) at % 25C (41,48,49). The complex modulus thus measured
includes the effect of series compliance, which may (50) or may not (51)
affect the apparent rate constants depending on reports. However, the series
compliance is not a concern for this report, because it is not changed
between mutants and the WT control.
The apparent rate constant 2pb and 2pc were studied as functions of the
MgATP, Pi, and MgADP concentrations. The data were fitted to the
following equations, which were derived from Scheme 1, assuming that
steps 0, 1, and 5 are in fast equilibrium, and that step 6 is the slowest
forward step of the cross-bridge cycle (52),
2pc ¼ K1S
1 þ K1Sk2 þ k2; (3)
2pb ¼ sk4 þ K5P
1 þ K5Pk4; (4)
where
s ¼ K2K1S
1 þ ð1 þ K2ÞK1S; (5)
and S ¼ [MgATP] and P ¼ [Pi]. The value K1 is the ATP association
constant, k2 is the forward rate constant of cross-bridge detachment step
2, and k2 is its reversal step. The value k4 is the forward rate constant of
the force generation step 4, and k4 is its reversal step. K5 is the Pi associ-
ation constant. The value s in Eq. 5 was calculated from K1 and K2 obtainedBiophysical Journal 100(4) 1014–1023from the MgATP study and S ¼ 5 mM. The reconstituted myocardium was
studied with eight different MgATP concentrations (0.05, 0.1, 0.2, 0.5, 1, 2,
5, 10 mM) at a fixed Pi concentration (8 mM) and pCa 4.66 to deduce the
rate and association constants of steps 1 and 2. The effect of phosphate (Pi)
was studied at six different Pi concentrations (0, 2, 4, 8, 16, and 32 mM) in
the presence of a fixed MgATP concentration (5 mM) and pCa 4.66 to
deduce the rate and association constants of steps 4 and 5. The effect of
MgADP was studied at four different MgADP concentrations (0, 1, 2,
and 3 mM) at fixed Pi (8 mM) and MgATP (2 mM) concentrations and
pCa 4.66 to deduce the association constant of step 0 (Scheme 1).RESULTS
pCa-tension and pCa-stiffness studies
To determine the effect of HCM-related Tm mutations on
cooperative activation and Ca2þ sensitivity, we studied
tension and stiffness of the thin filament-reconstituted
myocardium as functions of [Ca2þ]. pCa-tension plots com-
paring mutant and WT Tms are shown in Fig. 1. It is clear
that all three mutants affected the pCa-tension relationship,
with E180G having the greatest effect and D175 the small-
est. The effects of the three mutations on several parameters
are summarized in Fig. 2. All three mutants showed signif-
icantly increased (2–3.5) TLC compared to WT (p <
0.0001), indicating that the relaxation of myocardium is
partially impaired under diastolic condition.
Cooperativity (nH) was calculated by averaging the nH of
individual curves (Fig. 2 C). All three mutants showed
decreased cooperativity compared to WT, as indicated by
decreased nH (WT 2.79 5 0.26, V95A 1.70 5 0.12,
D175N 1.87 5 0.09, and E180G 1.75 5 0.14; see Table
S3). In the case of E180G-Tm, this may seem to contradict
the fact that the slopes (fnH) of the curve shown in Fig. 1 C
appear to be similar to WT-Tm; however, this is the result of
the averaging procedure. Here, the data points for the same
FIGURE 1 pCa-tension plots comparing the effects of three mutant Tms to those of WT-Tm. Experiments were performed at 25C. Symbols represent the
mean5 SE (solid line for WT, dashed line for mutants). Curves are the results of fitting the data to Eq. 1. Definitions of TLC, THC, and Tact are illustrated.
Impaired Relaxation in Tm HCM Mutations 1017pCa value were averaged, whereas averaged nH was ob-
tained by averaging individually fitted nH. (For a further
discussion on this subject, see the Supporting Material.)
pCa50 of V95A (6.20 5 0.06, N ¼ 13) and E180G
(6.49 5 0.02, N ¼ 11) was significantly larger than WT
(5.855 0.03, N ¼ 7), indicating increased Ca2þ sensitivity
of mutants, whereas pCa50 of D175N (5.885 0.05 N ¼ 15)
remained similar to WT (Fig. 2 D).Sinusoidal analysis and cross-bridge kinetics
Sinusoidal analysis was performed as described in Fujita
et al. (41) and Kawai and Brandt (47), to characterize the
elementary steps of the cross-bridge cycle of the reconsti-
tuted myocardium. Nyquist plots comparing mutant Tms
(dashed line) and WT (solid line) are shown in Fig. 3;
data in panels A–C were obtained at pCa 8, whereas panels
D–F depict data obtained at pCa 4.66. The Nyquist plot of
WT demonstrates that cross bridges actively cycled and
performed energy transduction even at pCa 8 (Fig. 3 A),
as reported earlier for the myocardium (53), because
processes B and C (represented by two semicircles) areFIGURE 2 Tension, stiffness, cooperativity, and pCa50. (A) Result of the tens
WT. Only the E180G-Tm mutant showed significantly higher THC than WT. The
E180G remained similar to WT. (B) Result of the stiffness study. The trends are
active stiffness in the case of V95Awas not significantly different from that of
ativity was reduced compared to that for WT. (D) Results of the pCa50 (Ca
2þ s
greater than that of WT, but the pCa50 of D175N was similar to that of WT. Teclearly present. The diameter of semicircles is proportional
to the number of actively cycling cross bridges (52). Fig. 3,
D–F, shows Nyquist plots at pCa 4.66 (25C) together with
those at the relaxing solution (containing 40 mM BDM; see
Table S2) at 0C.
The data in Fig. 3, A–C, demonstrates that, in the case of
WT, ~17% of cross bridges are active at pCa 8 compared
to pCa 4.66. The diameter of the Nyquist plots doubled
(2–2.3) in all three mutants, demonstrating that 31–39%
of cross bridges are actively cycling at pCa 8, which
demonstrates impaired relaxation. We conclude, therefore,
that the elevated TLC and YLC of mutants at pCa 8 are caused
by actively cycling cross bridges. Tact of V95A (1.10 5
0.07, N¼ 12) and D175N (1.125 0.08, N¼ 8) were signif-
icantly reduced (~28%) from WT (1.52 5 0.09, N ¼ 11),
indicating decreased myocardial contractility in mutants,
whereas E180G showed similar Tact (1.48 5 0.11, N ¼
10) to WT. E180G showed significantly higher THC
(~18%) than WT, but THC of V95A and D175N remained
similar to WT. This is mainly because E180G showed
similar Tact. A similar trend can be seen in stiffness
(Fig. 2 B).ion study. All three mutants showed significantly elevated TLC compared to
Tact of V95A and D175N was significantly less than that of WT, but that of
approximately the same as for the tension study in panel A, except that the
WT. (C) Results of the cooperativity study. In all three mutants the cooper-
ensitivity) study. The V95A and E180G both exhibited pCa50 significantly
nsion and stiffness are normalized to Ta. The asterisk (*) is p < 0.05.
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FIGURE 3 Nyquist plots of the mutants and WT. Nyquist plots of the mutants (dashed line) compared to WT (solid line) at 25C. (A–C) Three mutants are
compared to WTat pCa 8.0. (D–F) Three mutants are compared to WTat pCa 4.66. Also included in panelsD–F is the baseline taken in the relaxing solution
at 0C (þ for the mutant, and  for WT). Range of frequency used is 0.13–100 Hz. The frequency increases in the clockwise direction, and the rightmost
point corresponds to 100 Hz. Note the difference in scales for both axes in panels A–C versus panels D–F.
1018 Bai et al.Two apparent rate constants, 2pb and 2pc, were mea-
sured by sinusoidal analysis, as functions of [MgATP],
[MgADP], and [Pi] (Fig. 4). It is clear that all mutants
showed some changes in the apparent rate constants, but
the changes were small. The rate and association constants
of the elementary steps as defined in Scheme 1 are collec-
tively referred to as kinetic constants. These were deduced
by fitting the ligand concentration dependence of the
apparent rate constants (52). The kinetic constants of the
mutants and WT are compared in Fig. 5.
All kinetic constants changed in mutants, but only the
following changes were significant (p < 0.05): E180G ex-
hibited ~35% increase in K0 compared to WT. D175N
exhibited ~30% increase in k2 and ~50% decrease in K5.
V95A showed the most changes in the kinetic constants: it
exhibited ~40% decrease in K0, ~50% decrease in K1,
~30% decrease in K2, ~60% decrease in K5, ~56% increase
in k2, and ~40% increase in k4. All three mutants showed
reduced K5 (for E180G: p ¼ 0.07), indicating that the Pi
release step is accelerated in these HCM mutants.Cross-bridge distribution and force per cross
bridge
There are two main possibilities to explain the observed
change in isometric tension (Fig. 2 A)—1), a change in
either the number of force-generating cross bridges, or 2),
the force generated by each cross bridge. To discriminate
between these possibilities, we calculated the distributionBiophysical Journal 100(4) 1014–1023of cross bridges in each state under the standard activating
conditions (Table S2) as described in Zhao et al. (54), and
the result is shown in Fig. 6. All three mutants showed
a significant increase in the AM*D state (~2, p < 0.05)
compared to WT, which is consistent with the decrease in
K5 (Fig. 4). D175N showed ~30% decrease in AM*S
compared to WT. Att indicates the sum of all strongly
attached (force-generating) cross bridges:
Att ¼ AMD þ AM þ AMS þ AMDP þ AMD:
Only V95A showed a significant increase in the Att state
compared to WT (by 19 5 4%), but Xatt of D175N or
E180G is not significantly different from WT. Conse-
quently, THC per cross bridge (¼ THC/Xatt) decreased from
WT by 215 6% in V95A (5 with error propagation), re-
mained similar in D175N, but increased by 13 5 6% in
E180G.DISCUSSION
The clinical manifestations of HCM are highly diverse and
appear to be linked to both genetic and nongenetic factors
(55). However, there are emerging lines of evidence sup-
porting the concept that sarcomeres should be considered
as a key part in cardiac contractile function and its regula-
tion, rather than a simple assembly of force generators
(56–59). The biochemical properties of cardiac sarcomeres
have been shown to be directly responsible for many, if
FIGURE 4 Apparent rate constants. The apparent rate constants for myocardium reconstituted with mutants (dashed line) and WT (solid line) Tm.
Symbols represent the mean5 SE. Solid curves were generated by fitting the data to Eq. 3 (A–C) or Eq. 4 (D–F). (A–C) 2pc is plotted against [MgATP].
(D–F) 2pb is plotted against [Pi].
Impaired Relaxation in Tm HCM Mutations 1019not all, of the mechanical properties of the heart (60–63). As
the key component of the thin-filament regulatory mecha-
nism and the excitation-contraction coupling process,
Tm’s normal function is vital for maintaining the efficient
contractility of the heart. In this report, we investigated early
consequences of the gene alterations of Tm, which eventu-
ally leads into HCM.
Previous studies have shown that the mutant protein
expression level may be an important factor, because human
HMC patients are heterozygotes, and 100% expression levelcannot be achieved in transgenic animals (64). In our
studies, we started from the other extreme (100% mutant
proteins) where the effects are expected to be the largest.
Some of our results (increased pCa50 in V95A-Tm and
E180G-Tm) are consistent with previous studies
(34,35,37). In other studies, D175N also showed increased
pCa50 (31,33) at a lower expression level, which is at vari-
ance from our result. This difference may indicate that the
interaction between normal and mutant protein might
contribute to the sarcomeric dysfunction.FIGURE 5 Kinetic constants. The kinetic con-
stants of the reconstituted myocardium as shown
in Scheme 1. These were deduced using sinusoidal
analysis, as for Fig. 4. (A) Rate constants: V95A
showed increased k2 (305 1 s
1) and k4 (8.35
0.6 s1) compared to WT (k2 ¼ 195 1 s1 and
k4 ¼ 5.95 0.7 s1); D175N showed increased k2
(33 5 2 s1) compared to WT (26 5 2 s1). (B)
Equilibrium constants: V95A showed decreased
K0 (15 5 1 mM
1), K1 (0.9 5 0.2 mM
1), K2
(0.95 0.1), andK5 (0.225 0.04mM
1) compared
toWT (K0¼ 255 3mM1;K1¼ 1.85 0.4mM1;
K2 ¼ 1.4 5 0.1; and K5 ¼ 0.58 5 0.13 mM1).
D175N showed decreased K5 (0.26 5
0.04 mM1), and E180G showed increased K0
(33 5 1 mM1) compared to WT. None of the
mutants showed any significant change in K4. The
asterisk (*) is p < 0.05.
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FIGURE 6 Cross-bridge distributions. The cross-bridge distribution over
six states in three mutants in the standard activating solution (5S8P, see
Table S2) was calculated from the equilibrium constants (Fig. 5 B). The
Att indicates the sum of all strongly attached (force generating) cross
bridges. All three mutants showed significant increases (V95A, 18 5
3%; D175N, 16 5 2%; E180G, 17 5 3%) in the AM*D state compared
to WT (8 5 2%). D175N (19 5 2%) showed a significant decrease in
the AM*S state compared to WT (26 5 2%). V95A (77 5 2%) showed
an increase in the Att state compared to WT (65 5 1%). The asterisk (*)
is p < 0.05.
1020 Bai et al.Tmmutations D175N and E180G are located in a putative
TnT2 binding region (65) and both cause a charge change
from 1 to 0, which is thought to increase the local flexi-
bility of Tm and affect its interaction with the Tn complex.
V95A is located at the d-position of the heptad repeat, which
is critical for stabilization of the local coiled-coil structure
of Tm. This mutation introduces an Ala residue into region
2 of Tm. Consequently, it is possible that these three mutants
cause a shift in equilibrium between the closed state and the
open state in the three-state model (66) and subsequently
result in elevated tension under diastolic conditions (as
shown by elevated TLC). This also indicates that there exist
at least two different mechanisms affecting three-state equi-
librium, because these three mutants are located in two
different regions. D175N and E180G altered cross-bridge
kinetics to a lesser extent than V95A, which implies that
residue 95 of Tm is not only involved in Ca2þ-activation
but also in the cross-bridge cycle during the open state.
Evidence from in vitro studies has indicated that the substi-
tution of Gly for Glu in the e-position of the coiled-coil
structure destabilizes a-helix formation by 3, whereasTABLE 1 Comparison of HCM symptoms and possible molecular p
Sarcomeric dysfunction M
V95A nH Y TLC[ Tact Y pCa50 [ K0 Y K1 Y K2 Y
K5 Y k2 [ k4 [
D175N nH Y TLC [ Tact Y K5 Y k2 [ 20.35
E180G nH Y TLC [ pCa50[ K0 Y
Biophysical Journal 100(4) 1014–1023the effect is less dramatic with the mutation D175N
(67,68). E180G, despite its close proximity to D175N and
the similar role it plays in heptad repeat, showed a higher
TLC (P ¼ 0.067), Tact (P < 0.05), THC (P < 0.0005), and
pCa50 (P< 0.001) than D175N. From these results, we infer
that E180G can induce greater flexibility of Tm into the
adjacent region, causing a greater shift in equilibrium
between the closed state and the open state, and possibly
enhancing the hydrophobic interaction that takes place in
force generation.
Left ventricular hypertrophy (LVH) is the most obvious
and important clinical feature of HCM. From the functional
perspective, LVH is generally considered to be a compensa-
tory mechanism for the decreased contractility of the HCM
heart (5). The sarcomeric dysfunction deduced from this
study, maximum left ventricular wall thickness (LVWT),
and cumulative survival rate of the three Tm mutants are
summarized in Table 1. Results from clinical studies indi-
cate that patients with HCM caused by D175N exhibit
more serious LVH than E180G and higher cumulative
survival rate than V95A (69); E180G has been associated
with milder LVH than D175N, but its cumulative survival
rate is not reported (70,71). In a transgenic mouse study,
E180G exhibited severe LVH and significantly lower cumu-
lative survival rate than D175N at an expression level of
~60% (33,35), which is at variance with the patient studies.
Such differences are also seen in some patient studies and
likely reflect different genetic backgrounds and environ-
mental factors.
After comparing sarcomeric dysfunction, maximum
LVWT, and cumulative survival rate for the three Tm
mutants, we note the following:a) HCM pathogenesis may be related to impaired
relaxation of the myocardium
All three a-Tm mutants showed a significantly increase in
the number of cycling cross bridges (from 17% to 31–
39%) at pCa 8, as evidenced by increased magnitudes B
and C (Fig. 3) (47,52). This results in significantly elevated
tension (TLC: 2–3.5) and stiffness (YLC: 2) (Fig. 2). We
conclude, therefore, that the increase in cycling cross
bridges at pCa 8 is the direct cause of the diastolic failure
manifested in Tm-related HCM. This mechanism has been
previously proposed based on indirect evidence (34,37),
but we now demonstrate this directly. Elevated number ofathogenesis
aximum LVWT (Ref.) Cumulative survival rate (Ref.)
165 6 mm (37) Low, similar to that of MHC7
mutation R403Q (37)
3.1 mm, significantly greater
than for E180G (70)
Significantly higher than for MHC7
mutation R403Q (69)
12.55 4.7 mm (70) Not studied
Impaired Relaxation in Tm HCM Mutations 1021cycling cross bridges at pCa 8 will inevitably contribute to
diastolic dysfunction: pCa~7 was reported as the diastolic
Ca2þ concentration in rat (74). This intrinsic and permanent
diastolic pressure overload is capable of stimulating cardiac
growth, which leads to an increased release of angiotension
II and aldosterone (75), and results in phenotypic alterations
at the myocyte level (76)—hypertrophy (77) and abnormal
extracellular matrix formation (75).
Thus, elevated tension at pCa 8 can lead to impaired LV
filling causing diastolic dysfunction. The thickened myocar-
dium, structural changes including cellular disorganization,
and enhanced interstitial fibrosis (16) should thus be consid-
ered as either compensatory mechanisms or symptoms
caused by HCM. Elevated diastolic tension and stiffness
can also help explain the enhanced LV end-diastolic pres-
sure and decreased LV end-diastolic volume. In addition,
reduced cooperativity for all three mutants indicates
impaired coupling among Tn, Tm, actin, and myosin, which
also occurs in dilated cardiomyopathy-related a-Tm muta-
tions (12).b) LVH and elevated Ca2þ-sensitivity may
compensate for decreased contractility
Marian (8) has proposed that decreased contractility would
result in increased stimulus for cardiomyocytes to produce
trophic factors, resulting in hypertrophy and interstitial
fibrosis. This proposal is supported by the comparison
between E180G and D175N mutations. Tact was similar to
WT in E180G-Tm containing myocardium, whereas Tact
was ~28% less than WT with D175N-Tm myocardium
(Fig. 2); LVWT of E180G-Tm is significantly less than
that with D175N-Tm (Table 1) (70,71). V95A myocardium,
however, exhibited an ~28% reduction in Tact as with
D175N (Fig. 2), but LVWTwas similar to E180G (Table 1),
which may explain the lower cumulative survival rate for
patients with V95A mutation than D175N mutation due to
inadequate compensation from LVH.
It has been reported that elevated Ca2þ sensitivity is asso-
ciated with HCM (12,38), consistent with our observations
on myocardium containing V95A- and E180G-Tm (Figs.
1 and 2). Previous studies also reported decreased Ca2þ
sensitivity in dilated cardiomyopathy a-Tm mutants
(12,37). HCM myosin mutant R403Q has been shown to
cause a similar decrease in Tact (~30%) (78) and a signifi-
cantly higher level of LVH than V95A (37), but their cumu-
lative survival rate is similar. This may be because, similar
to our results with D175N-Tm (Figs. 1 and 2), the myosin
mutation R403Q has little effect on the Ca2þ sensitivity of
isometric force production (79).CONCLUSIONS
Based on the results we present here, we conclude that the
impaired relaxation and elevated Ca2þ sensitivity are themajor cause of Tm mutation-related HCM pathogenesis.
A decrease in active tension may contribute to the hyper-
trophy of cardiomyocytes, as well as to the severity of symp-
toms and disease prognosis.SUPPORTING MATERIAL
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